ArticlePloS one2017
Study of association and molecular analysis of human papillomavirus in breast cancer of Indian patients: Clinical and prognostic implication.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- HPV in breast cancer: prevalence and comparison with healthy tissue-a systematic review and meta-analysis.Cancer causes & control : CCC · 2026Pooled it
- The oncogenic role of human papillomavirus in breast cancer: a comprehensive systematic review and meta-analysis.Frontiers in microbiology · 2025Pooled it
- An updated systemic review and meta-analysis on human papillomavirus in breast carcinogenesis.Frontiers in oncology · 2023Pooled it
- Absence of high-risk human papillomavirus in breast cancer tissues from young BRCA1/BRCA2-negative women.BMC women's health · 2026Article
- HPV-driven breast carcinogenesis: associations with tumor severity, Ki67 expression and metastasis.Infectious agents and cancer · 2025Article
- Methylation sites of human papillomavirus 16 as potential biomarkers for cervical cancer progression.Frontiers in oncology · 2025Article
- HPV, APOBEC3B, and the origins of breast cancer: a narrative review and perspectives on novel mechanisms.Frontiers in oncology · 2025Review
- Review
- The association between infectious agents and breast cancer: a review of the epidemiologic evidence.Breast cancer research and treatment · 2024Review
- The viral origins of breast cancer.Infectious agents and cancer · 2024Review
- Cationic Liposomes Carrying HPV16 E6-siRNA Inhibit the Proliferation, Migration, and Invasion of Cervical Cancer Cells.Pharmaceutics · 2024Article
- Article
- The Role of Oncogenic Viruses in the Pathogenesis of Sporadic Breast Cancer: A Comprehensive Review of the Current Literature.Pathogens (Basel, Switzerland) · 2024Review
- Human papillomaviruses and breast cancer: A systematic review and meta‑analysis.Oncology letters · 2024Article
- Low presence of papillomavirus and its lack of correlation with clinicopathological factors in breast cancer: a case control study.Iranian journal of microbiology · 2023Article
- HPV-Associated Breast Cancer: Myth or Fact?Pathogens (Basel, Switzerland) · 2022Review
- Presence of Human Papillomavirus DNA in Malignant Neoplasia and Non-Malignant Breast Disease.Current issues in molecular biology · 2022Article
- Interrelated Oncogenic Viruses and Breast Cancer.Frontiers in molecular biosciences · 2022Review
- High-Risk Human Papillomavirus Oncogenic E6/E7 mRNAs Splicing Regulation.Frontiers in cellular and infection microbiology · 2022Review
- Low frequency of HPV positivity in breast tumors among patients from south-central Poland.Infectious agents and cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHuman papillomavirus (HPV) causes tumors primarily Cervical cancer. Recently, inconsistent reports came up in Breast cancer (BC) too. In India, despite treatment 70,218 BC patients die each year. So, we explored the association of HPV, if any, with BC prognosis in Indian pre-therapeutic (PT) and Neo-adjuvant chemotherapy (NACT) patients with subsequent analysis of HPV profile.
methodsHPV prevalence was checked and analysis of physical status, copy number, genome variation, promoter methylation and expression (mRNA and protein) of the prevalent subtype was done.
resultsHigh prevalence of HPV was observed in both PT (64.0%) and NACT (71.0%) cases with significant association with younger (20-45 yrs) PT patients. Interestingly, HPV infection was significantly increased from adjacent normal breast (9.5%, 2/21), fibro adenomas (30%, 3/10) to tumors (64.8%, 203/313) samples. In both PT and NACT cases, HPV16 was the most prevalent subtype (69.0%) followed by HPV18 and HPV33. Survival analysis illustrated hrHPV infected PT patients had worst prognosis. So, detailed analysis of HPV16 profile was done which showed Europian-G350 as the most frequent HPV16 variant along with high rate of integration. Moreover, low copy number and hyper-methylation of P97 early promoter were concordant with low HPV16 E6 and E7 mRNA and protein expression. Notably, four novel variations (KT020838, KT020840, KT020841 and KT020839) in the LCR region and two (KT020836 and KT020837) in the E6 region were identified for the first time along with two novel E6^E7*I (KU199314) and E6^E7*II (KU199315) fusion transcript variants.
conclusionThus, significant association of hrHPV with prognosis of Indian BC patients led to additional investigation of HPV16 profile. Outcomes indicated a plausible role of HPV in Indian BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.